Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(72 sites) United States
Local Institution - 0117, New Haven, Connecticut Local Institution - 0134, Washington D.C., District of Columbia Local Institution - 0126, Orlando, Florida Local Institution - 0124, Iowa City, Iowa Local Institution - 0123, Baltimore, Maryland Washington University School of Medicine, St Louis, Missouri Local Institution - 0096, Hauppauge, New York Local Institution - 0135, Cincinnati, Ohio Local Institution - 0127, Cleveland, Ohio Local Institution - 0165, Charleston, South Carolina Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina Local Institution - 0158, Salt Lake City, Utah Local Institution - 0095, Seattle, Washington Argentina
Local Institution - 0154, Buenos Aires Local Institution - 0156, Buenos Aires Australia
Local Institution - 0076, North Ryde, New South Wales Local Institution - 0111, St Leonards, New South Wales Local Institution - 0074, South Brisbane, Queensland Local Institution - 0003, Malvern Brazil
Local Institution - 0093, Brasília, Federal District Canada
Local Institution - 0007, Calgary, Alberta Local Institution - 0109, Montreal, Quebec Local Institution - 0009, Montreal, Quebec Chile
Local Institution - 0105, Santiago, Santiago Metropolitan Local Institution - 0005, Santiago, Santiago Metropolitan Local Institution - 0163, Santiago Colombia
Local Institution - 0052, Cali Czechia
Local Institution - 0147, Prague, Praha 5 Local Institution - 0149, Brno Local Institution - 0150, Hradec Králové Finland
Local Institution - 0044, Helsinki, Etelä-Suomen Lääni Local Institution - 0029, Turku Local Institution - 0060, Vantaa France
Local Institution - 0083, Lille, Nord Local Institution - 0080, Boredeaux Local Institution - 0028, Villejuif Germany
Local Institution - 0025, Jena, Thuringia Local Institution - 0026, Hamburg Local Institution - 0014, Herne Local Institution - 0027, München Ireland
Local Institution - 0059, Dublin Local Institution - 0062, Dublin Italy
Local Institution - 0139, Verona, Veneto Local Institution - 0073, Milan Local Institution - 0087, Napoli Campania Japan
Local Institution - 0097, Koto-ku, Tokyo Local Institution - 0078, Toyoma, Toyama Local Institution - 0172, Fukuoka Mexico
Local Institution - 0046, Monterrey, Nuevo León Local Institution - 0048, Oaxaca City Local Institution - 0122, Puebla City Local Institution - 0049, Tlalpan Local Institution - 0108, Tlalpan Local Institution - 0118, Tlalpan Romania
Local Institution - 0103, Cluj-Napoca Local Institution - 0161, Craiova Local Institution - 0100, Iași Local Institution - 0101, Sibiu South Korea
Local Institution - 0112, Seoul, Seoul-teukbyeolsi [Seoul] Local Institution - 0017, Seoul, Seoul-teukbyeolsi Local Institution - 0167, Seoul Spain
Local Institution - 0013, Madrid Local Institution - 0091, Madrid Local Institution - 0043, Seville Switzerland
Local Institution - 0054, Chur HOCH Health Ostschweiz, Sankt Gallen Local Institution - 0056, Zurich United Kingdom
Royal Marsden Hospital (Chelsea), London, Kensington and Chelsea Local Institution - 0057, Cardiff Local Institution - 0019, London The Christie NHS Foundation Trust, Manchester Royal Marsden Hospital Sutton, Sulton, Surrey